-
公开(公告)号：US5437471A
公开(公告)日：1995-08-01
申请号：US138258
申请日：1993-10-20
申请人： Ryouichi Yoshida , Hiroaki Fujii , Atsushi Tsuji , Tomoko Shimizu , Nobuya Osada , Takahiro Yamanishi
发明人： Ryouichi Yoshida , Hiroaki Fujii , Atsushi Tsuji , Tomoko Shimizu , Nobuya Osada , Takahiro Yamanishi
CPC分类号： B60R21/0136 , B60R21/21 , B60R21/2644 , B60R21/33 , B60R2021/26029
摘要： An inflator with a starter for starting a gas generator of a side collision air bag device is formed of: a needle disposed in the side face of a vehicle and made movable from the outside to the inside of the vehicle; an elastic member for urging the needle in the opposite direction to the movement of the needle; and a priming powder disposed forward of the movement of the needle. When the priming powder is hit by the needle, the ignition agent of the gas generator ignites to inflate an air bag.
摘要翻译： 具有用于启动侧面碰撞气囊装置的气体发生器的起动器的充气机由以下部件形成：设置在车辆的侧面中的针，并且能够从车外的内部移动到内部; 弹性构件，用于沿与针的移动相反的方向推动针; 以及设置在针的运动之前的起动粉末。 当起动粉末被针刺时，气体发生器的点火剂点燃以使气囊膨胀。
-
公开(公告)号：US5375877A
公开(公告)日：1994-12-27
申请号：US138253
申请日：1993-10-20
申请人： Ryouichi Yoshida , Hiroaki Fujii , Takahiro Yamanishi , Tomoko Shimizu , Atsushi Tsuji , Nobuya Osada
发明人： Ryouichi Yoshida , Hiroaki Fujii , Takahiro Yamanishi , Tomoko Shimizu , Atsushi Tsuji , Nobuya Osada
CPC分类号： B60R21/0136 , H01H35/146
摘要： A lateral collision detector is formed of a wire extended along the inner face of the outer plate of an automotive door; and a signal output device adapted to be pulled and actuated by the wire.
摘要翻译： 横向碰撞检测器由沿着汽车门的外板的内表面延伸的线形成; 以及适于由线拉动和致动的信号输出装置。
-
公开(公告)号：US20080050601A1
公开(公告)日：2008-02-28
申请号：US11895895
申请日：2007-08-28
申请人： Noboru Otani , Tomoko Shimizu , Koji Imai
发明人： Noboru Otani , Tomoko Shimizu , Koji Imai
CPC分类号： G02B1/14 , C08G77/14 , C08J7/047 , C08J2483/00 , C08K3/22 , C09D183/04 , C09D183/06 , C09D183/08 , G02B1/105 , G02B1/115
摘要： Applying liquid for hard coating that is made of organic silane compounds, the fine particles of composite mainly based on titanium-oxide, which also includes zirconium-oxide and silicon-oxide etc., dicyandiamide, itaconic acid, and Co(II) acetylacetonate compound on plastic lenses in order to form a hard coating layer after hardening.
摘要翻译： 应用由有机硅烷化合物制成的硬涂层的液体，主要基于二氧化钛的复合微粒，其还包括氧化锆和氧化硅等，双氰胺，衣康酸和乙酰丙酮酸Co（II）化合物 在塑料镜片上，以硬化后形成硬质涂层。
-
公开(公告)号：US20130108849A1
公开(公告)日：2013-05-02
申请号：US13808443
申请日：2011-04-04
IPC分类号： H01L31/048 , C09D167/02
CPC分类号： C09D167/02 , B32B27/20 , B32B27/36 , B32B2307/402 , C08J5/18 , C08J2367/02 , C08K3/22 , C08K5/5313 , C08K5/5317 , H01L31/049 , Y02E10/50 , Y10T428/24975
摘要： A polyester film for protecting a rear surface of a solar cell contains a white polyester film layer containing a polyester composition containing 85 to 96% by weight of polyethylene terephthalate that is polymerized with an antimony compound and/or a titanium compound as a polycondensation catalyst and 4 to 15% by weight of rutile type titanium oxide particles, the polyester composition containing, based on the molar number of the total dicarboxylic acid component constituting the polyethylene terephthalate, 10 to 40 millimole % of a particular phosphoric acid compound and 2 to 50 millimole % in total in terms of metal elements of antimony element and/or titanium element derived from the polycondensation catalyst.
摘要翻译： 用于保护太阳能电池的后表面的聚酯膜含有含有聚酯组合物的白色聚酯膜层，该聚酯组合物含有85至96重量％的聚芴化合物和/或作为缩聚催化剂的钛化合物聚合的聚对苯二甲酸乙二醇酯， 4〜15重量％的金红石型氧化钛粒子，所述聚酯组合物以构成聚对苯二甲酸乙二醇酯的总二羧酸成分的摩尔数为基准，含有10〜40毫摩尔的特定磷酸化合物和2〜50毫摩尔 以衍生自缩聚催化剂的锑元素和/或钛元素的金属元素为基准计算。
-
公开(公告)号：US09175080B2
公开(公告)日：2015-11-03
申请号：US13876763
申请日：2011-09-28
IPC分类号： A61K39/395 , C07K16/28 , C07K17/00 , G01N33/88
CPC分类号： C07K16/28 , C07K16/2869 , C07K17/00 , C07K2317/24 , C07K2317/76 , G01N33/88
摘要： It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
摘要翻译： 本发明的目的是提供结合人PGE2受体亚型EP4并抑制EP4的功能的抗体或其功能性片段。 本发明的另一个目的是提供一种包含上述抗体或其功能片段的药物。 用人PGE2受体亚型EP4免疫小鼠，并筛选抑制EP4诱导的细胞内cAMP水平升高的单克隆抗体。 另外，测定得到的单克隆抗体的CDR序列。
-
6.发明授权Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier 有权抗人CCR7抗体，杂交瘤，核酸，载体，细胞，药物组合物和抗体固定载体公开(公告)号：US08865170B2
公开(公告)日：2014-10-21
申请号：US13876265
申请日：2011-09-27
申请人： Naoki Nishiguchi , Akiyoshi Hirayama , Masahiro Furutani , Tatsuo Shimizu , Kiyoshi Takayama , Tomoko Shimizu , Kazuya Suzuki
发明人： Naoki Nishiguchi , Akiyoshi Hirayama , Masahiro Furutani , Tatsuo Shimizu , Kiyoshi Takayama , Tomoko Shimizu , Kazuya Suzuki
IPC分类号： C07K16/28 , A61K31/713 , A61K39/00
CPC分类号： C07K16/2866 , A61K31/713 , A61K2039/505 , C07K2317/70 , C07K2317/76
摘要： The present invention is novel anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibodies useful for treating tissue fibrosis or cancer, and pharmaceutical compositions containing the anti-human-CCR7 antibodies. The invention includes an anti-human-CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77. The invention also includes an anti-human-CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.
摘要翻译： 本发明是可用于治疗组织纤维化或癌症的新型抗人CC-基质受体-7（抗人CCR7）抗体，以及含有抗人CCR7抗体的药物组合物。 本发明包括与人CCR7的细胞外结构域特异性结合的抗人CCR7抗体，其具有含有SEQ ID NO：7，SEQ ID NO：17，SEQ ID NO：27所示氨基酸序列的重链CDR3， SEQ ID NO：37，SEQ ID NO：47，SEQ ID NO：57，SEQ ID NO：67或SEQ ID NO：77.本发明还包括具有重链CDR 1-3的抗人CCR7抗体， 含有由SEQ ID NO：5-10，15-20,25-30,35-40,45-50,55-60,65-70或75-80表示的氨基酸序列的轻链CDR1-3。 优选地，抗体具有干扰由CCR7配体刺激引起的CCR7依赖性细胞内信号转导机制的活性。
-
公开(公告)号：US20130195869A1
公开(公告)日：2013-08-01
申请号：US13876265
申请日：2011-09-27
申请人： Naoki Nishiguchi , Akiyoshi Hirayama , Masahiro Furutani , Tatsuo Shimizu , Kiyoshi Takayama , Tomoko Shimizu , Kazuya Suzuki
发明人： Naoki Nishiguchi , Akiyoshi Hirayama , Masahiro Furutani , Tatsuo Shimizu , Kiyoshi Takayama , Tomoko Shimizu , Kazuya Suzuki
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K31/713 , A61K2039/505 , C07K2317/70 , C07K2317/76
摘要： An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.
-
公开(公告)号：US20130197199A1
公开(公告)日：2013-08-01
申请号：US13876763
申请日：2011-09-28
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , C07K16/2869 , C07K17/00 , C07K2317/24 , C07K2317/76 , G01N33/88
摘要： It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
摘要翻译： 本发明的目的是提供结合人PGE2受体亚型EP4并抑制EP4的功能的抗体或其功能性片段。 本发明的另一个目的是提供一种包含上述抗体或其功能片段的药物。 用人PGE2受体亚型EP4免疫小鼠，并筛选抑制EP4诱导的细胞内cAMP水平升高的单克隆抗体。 另外，测定得到的单克隆抗体的CDR序列。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.029 秒)